Literature DB >> 16978601

Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.

Kenjiro Matsumoto1, Yoshio Hatori, Toshihiko Murayama, Kimihito Tashima, Sumphan Wongseripipatana, Kaori Misawa, Mariko Kitajima, Hiromitsu Takayama, Syunji Horie.   

Abstract

7-hydroxymitragynine, a constituent of the Thai herbal medicine Mitragyna speciosa, has been found to have a potent opioid antinociceptive effect. In the present study, we investigated the mechanism of antinociception and the inhibitory effect on gastrointestinal transit of 7-hydroxymitragynine, and compared its effects with those of morphine. When administered subcutaneously to mice, 7-hydroxymitragynine produced antinociceptive effects about 5.7 and 4.4 times more potent than those of morphine in the tail-flick (ED50=0.80 mg/kg) and hot-plate (ED50=0.93 mg/kg) tests, respectively. The antinociceptive effect of 7-hydroxymitragynine was significantly blocked by the mu1/mu2-opioid receptor antagonist beta-funaltrexamine hydrochloride (beta-FNA) and the mu1-opioid receptor-selective antagonist naloxonazine in both tests. Thus, 7-hydroxymitragynine acts predominantly on mu-opioid receptors, especially on mu1-opioid receptors. Isolated tissue studies further supported its specificity for the mu-opioid receptors. Further, 7-hydroxymintragynine dose-dependently (ED50=1.19 mg/kg, s.c.) and significantly inhibited gastrointestinal transit in mice, as morphine does. The inhibitory effect was significantly antagonized by beta-FNA pretreatment, but slightly antagonized by naloxonazine. The ED50 value of 7-hydroxymitragynine on gastrointestinal transit was larger than its antinociceptive ED50 value. On the other hand, morphine significantly inhibits gastrointestinal transit at a much smaller dose than its antinociceptive dose. These results suggest that mu-opioid receptor mechanisms mediate the antinociceptive effect and inhibition of gastrointestinal transit. This compound induced more potent antinociceptive effects and was less constipating than morphine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978601     DOI: 10.1016/j.ejphar.2006.08.013

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  31 in total

1.  The Right to Use Kratom from the Psychiatric and Islamic Perspectives.

Authors:  Mohammad Farris Iman Leong Bin Abdullah; Mohd Afifuddin Mohamad; Noor Naemah Abdul Rahman
Journal:  J Relig Health       Date:  2021-04

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 3.  Ethnobotany as a pharmacological research tool and recent developments in CNS-active natural products from ethnobotanical sources.

Authors:  Will C McClatchey; Gail B Mahady; Bradley C Bennett; Laura Shiels; Valentina Savo
Journal:  Pharmacol Ther       Date:  2009-05-05       Impact factor: 12.310

4.  Plants with Anti-Addictive Potential.

Authors:  Eduardo Luis Konrath; Marcelo Dutra Arbo; Bruno Dutra Arbo; Mariana Appel Hort; Elaine Elisabetsky; Mirna Bainy Leal
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

6.  Prostatic relaxation induced by loperamide is mediated through activation of opioid μ-2 receptors in vitro.

Authors:  Chih-Cheng Lu; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

7.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

8.  Opiate-induced constipation related to activation of small intestine opioid μ2-receptors.

Authors:  Wency Chen; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

9.  Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a μ-opioid agonist, in rat plasma and its application to a pharmacokinetic study.

Authors:  Pradeep K Vuppala; Seshulatha Jamalapuram; Edward B Furr; Christopher R McCurdy; Bonnie A Avery
Journal:  Biomed Chromatogr       Date:  2013-07-25       Impact factor: 1.902

10.  Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice.

Authors:  Kenjiro Matsumoto; Minoru Narita; Naotaka Muramatsu; Terumi Nakayama; Kaori Misawa; Mariko Kitajima; Kimihito Tashima; Lakshmi A Devi; Tsutomu Suzuki; Hiromitsu Takayama; Syunji Horie
Journal:  J Pharmacol Exp Ther       Date:  2013-12-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.